Last reviewed: June 7, 2026
Last updated: June 7, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Two major weight loss medications—semaglutide and tirzepatide—work through overlapping but distinct biological pathways. While semaglutide targets the GLP-1 receptor, tirzepatide activates both GLP-1 and GIP receptors, making it a dual-action compound. Clinical trials show tirzepatide users experienced greater average weight loss compared to semaglutide users over the same period.
How Semaglutide and Tirzepatide Differ in Mechanism
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone that signals fullness to your brain and slows stomach emptying. This single-receptor approach reduces appetite and helps regulate blood sugar levels. The medication has been studied extensively in weight loss trials since 2021 and remains a trusted first-line option for many patients seeking metabolic support.
Tirzepatide works as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. By activating both pathways simultaneously, tirzepatide targets appetite control through two independent mechanisms while also enhancing insulin secretion. This dual-receptor activation may explain why some patients experience more pronounced weight reduction with tirzepatide than they would with semaglutide alone.
Clinical Evidence: Weight Loss Results Comparison
Head-to-head trials have documented measurable differences in weight loss outcomes between these two compounds. In the SURPASS trials, tirzepatide demonstrated weight reductions ranging from 15% to 22% of baseline body weight depending on dose level, while earlier semaglutide trials (STEP program) showed reductions between 9% to 18%. Both medications significantly outperform diet and exercise alone, but tirzepatide's dual-receptor mechanism appears to amplify metabolic effects.
Individual response varies based on genetics, lifestyle, and metabolic factors. Some patients achieve their weight loss goals efficiently with semaglutide, while others respond more dramatically to tirzepatide's dual action. PlexusDx offers the Precision Peptide Genetic Test to identify your individual response patterns across 14 metabolic pathways, helping guide whether semaglutide or tirzepatide aligns better with your genetic profile.
Combination Therapy: The GLP-Squared Approach
Some patients and prescribers explore combining semaglutide and tirzepatide for enhanced metabolic support, though this remains a specialized approach. PlexusDx offers the GLP-Squared Injection, which combines both compounds in a single injection starting at $249/month, and GLP-Squared Oral formulations for patients preferring tablets. This dual-compound strategy leverages both the established single-receptor benefits of semaglutide and the dual-receptor advantages of tirzepatide in one prescription.
Combination therapy requires careful monitoring and medical supervision to ensure safety and efficacy. Your PlexusDx provider will assess whether dual-compound treatment makes sense based on your weight loss plateau, metabolic markers, and tolerance to monotherapy. The combination approach is most commonly considered for patients who have achieved partial results on one medication alone and seek additional metabolic support.
Choosing Between Semaglutide and Tirzepatide for Your Goals
Semaglutide remains an excellent entry point for many patients due to its established safety profile, lower starting cost ($149/month), and robust long-term data. Patients who respond well to single-mechanism therapy, prefer slower dose escalation, or have specific contraindications to dual-receptor activation often achieve meaningful results with semaglutide alone. PlexusDx offers compounded semaglutide injections and oral formulations at flat monthly rates with no price increases as your therapeutic dose adjusts.
Tirzepatide may be preferable if you require more aggressive metabolic support, have plateaued on other medications, or show genetic predisposition toward GIP-pathway responsiveness. Starting at $249/month, PlexusDx compounded tirzepatide injections offer flat-rate pricing regardless of dose strength. Your provider can recommend tirzepatide if your Precision Peptide Genetic Test reveals favorable variants in the GIP receptor (GIPR rs1800437) or related metabolic genes, indicating potential for enhanced response to dual-receptor activation.
Cost, Access, and Genetic Personalization at PlexusDx
PlexusDx serves all 50 states without requiring insurance, membership fees, or lengthy authorization delays. Compounded semaglutide injection starts at $149/month, while compounded tirzepatide injection begins at $249/month—both available through licensed 503A compounding pharmacies. HSA and FSA accounts are accepted, making precision weight loss therapy accessible to a broader range of patients seeking personalized metabolic support without insurance barriers.
The Precision Peptide Genetic Test ($99 add-on after your first month of treatment) maps 14 metabolic pathways and 150+ genetic insights to reveal your individual peptide responsiveness profile. Testing identifies key variants such as GLP1R rs6923761, GIP receptor rs1800437, and FTO rs9939609, informing whether semaglutide, tirzepatide, or combination therapy aligns best with your genetic blueprint. This precision-guided approach helps optimize outcomes and ensures your selected medication matches your metabolic biology.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I take semaglutide and tirzepatide together?
Combining semaglutide and tirzepatide in a single protocol is possible under medical supervision, and PlexusDx offers the GLP-Squared Injection and GLP-Squared Oral for patients seeking this dual-compound approach. Combination therapy is typically reserved for patients who have plateaued on monotherapy and require enhanced metabolic support. Your PlexusDx provider will determine whether dual-compound treatment is appropriate based on your medical history and weight loss trajectory.
Which medication causes more weight loss: semaglutide or tirzepatide?
Clinical trials show tirzepatide users experienced greater average weight loss (15–22% of baseline weight) compared to semaglutide users (9–18%), though individual results vary significantly. The dual-receptor mechanism of tirzepatide activates both GLP-1 and GIP pathways, potentially amplifying appetite suppression and metabolic effects. However, some patients achieve excellent results with semaglutide alone, making genetic testing and personalized monitoring essential for optimizing your specific outcome.
How much does tirzepatide cost at PlexusDx?
PlexusDx compounded tirzepatide injection starts at $249/month at the base commitment tier, with your dose adjustable without price changes—ensuring predictable monthly costs regardless of therapeutic level. Oral tirzepatide begins at $279/month. Both formulations are available nationwide through licensed 503A compounding pharmacies, with HSA/FSA eligibility and no insurance requirement.
What are the side effects of semaglutide versus tirzepatide?
Both medications commonly cause mild gastrointestinal effects such as nausea, reduced appetite, and occasional vomiting during dose escalation, typically diminishing over weeks. Tirzepatide's dual-receptor activation may produce slightly higher initial nausea rates in some users, though most side effects resolve as your body adapts. Serious adverse events are rare with either medication when prescribed and monitored appropriately by a licensed provider.
How does the Precision Peptide Genetic Test help choose between semaglutide and tirzepatide?
The PlexusDx Precision Peptide Genetic Test ($99) reveals your genetic predisposition across 14 metabolic pathways, including GLP1R and GIP receptor variants that influence medication responsiveness. Favorable variants in GIP receptor rs1800437 or strong GLP1R rs6923761 expression may suggest enhanced response to tirzepatide's dual-receptor action, while other genetic profiles may optimize with semaglutide monotherapy. Testing guides your provider toward the medication most likely to align with your individual metabolic biology.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Does Tirzepatide Make You Feel? Insights into Its Effects and Experience
Navigating Fertility and Weight Loss: Can You Take Semaglutide While Trying to Get Pregnant?